Exubera, Exubera. What will become of you? That is the big question. Pfizer's eagerly awaited inhalable insulin device is nearing the market. For anyone following this saga, there is a must-read market analysis piece on Business Week's website. With the great title to boot: "From Pfizer, Irrational Exubera?"

The article looks at the big question everyone is asking about Exubera: will it be the blockbuster drug it's been hyped as? While Pfizer says it expects billions of dollars in sales (and the company is pouring millions into promoting the product), critics say it is an overhyped, overpriced product that could put some diabetics in danger of lung damage. Not to mention the device is the size of a county fair prize-winning squash! Who wants to suck on that in public?! Let alone tote it around. On the other hand, let's not forget it's big selling point: no needles. Yet critics maintain so-called needle phobia is not as widespread as Pfizer would have you believe.

If you check out this article, also take a look at the readers' comments at the end. There seems to be a fairly even split in opinion on this thing.